Hancock W W, Lu B, Gao W, Csizmadia V, Faia K, King J A, Smiley S T, Ling M, Gerard N P, Gerard C
Millennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139, USA.
J Exp Med. 2000 Nov 20;192(10):1515-20. doi: 10.1084/jem.192.10.1515.
Chemokines provide signals for activation and recruitment of effector cells into sites of inflammation, acting via specific G protein-coupled receptors. However, in vitro data demonstrating the presence of multiple ligands for a given chemokine receptor, and often multiple receptors for a given chemokine, have led to concerns of biologic redundancy. Here we show that acute cardiac allograft rejection is accompanied by progressive intragraft production of the chemokines interferon (IFN)-gamma-inducible protein of 10 kD (IP-10), monokine induced by IFN-gamma (Mig), and IFN-inducible T cell alpha chemoattractant (I-TAC), and by infiltration of activated T cells bearing the corresponding chemokine receptor, CXCR3. We used three in vivo models to demonstrate a role for CXCR3 in the development of transplant rejection. First, CXCR3-deficient (CXCR3(-/)-) mice showed profound resistance to development of acute allograft rejection. Second, CXCR3(-/)- allograft recipients treated with a brief, subtherapeutic course of cyclosporin A maintained their allografts permanently and without evidence of chronic rejection. Third, CXCR(+/+) mice treated with an anti-CXCR3 monoclonal antibody showed prolongation of allograft survival, even if begun after the onset of rejection. Taken in conjunction with our findings of CXCR3 expression in rejecting human cardiac allografts, we conclude that CXCR3 plays a key role in T cell activation, recruitment, and allograft destruction.
趋化因子通过特定的G蛋白偶联受体发挥作用,为效应细胞的激活和募集到炎症部位提供信号。然而,体外实验数据表明,给定趋化因子受体存在多种配体,且给定趋化因子通常也有多种受体,这引发了对生物学冗余性的担忧。在此我们表明,急性心脏移植排斥反应伴随着移植体内趋化因子10kD干扰素(IFN)-γ诱导蛋白(IP-10)、IFN-γ诱导的单核因子(Mig)和IFN诱导的T细胞α趋化因子(I-TAC)的渐进性产生,以及携带相应趋化因子受体CXCR3的活化T细胞的浸润。我们使用三种体内模型来证明CXCR3在移植排斥反应发展中的作用。首先,CXCR3缺陷(CXCR3(-/-))小鼠对急性移植排斥反应的发展表现出显著抗性。其次,接受短暂、亚治疗剂量环孢素A治疗的CXCR3(-/-)移植受体永久性地维持了其移植器官,且无慢性排斥反应迹象。第三,用抗CXCR3单克隆抗体治疗的CXCR(+/+)小鼠即使在排斥反应开始后开始治疗,也表现出移植器官存活时间延长。结合我们在排斥的人类心脏移植中发现的CXCR3表达情况,我们得出结论,CXCR3在T细胞激活、募集和移植器官破坏中起关键作用。